Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG Phase 2 randomized clinical trial

Importance: Because of socioeconomic factors, many patients with advanced non-small cell lung cancer (NSCLC) do not receive immunotherapy in the first-line setting. It is unknown if the combination of immunotherapy with chemotherapy can provide clinical benefits in immunotherapy-naive patients with...

Full description

Autores:

Arrieta, Oscar
Barrón-Barrón, Feliciano
Ramírez Tirado, Laura Alejandra
Zatarain-Barrón, Zyanya Lucia
Cardona-Mendoza, Andrés Felipe
Díaz-García, Diego
Yamamoto-Ramos, Masao
Mota-Vega, Beatriz
Carmona, Amir
Peralta-Alvarez, Marco Polo
Bautista, Yolanda
Aldaco, Fernando
Gerson, Raquel
Rolfo, Christian
Rosell, Rafael Costa

Tipo de recurso:

Article of journal

Fecha de publicación:

2020

Institución:

Universidad El Bosque

Repositorio:

Repositorio U. El Bosque

Idioma:

eng

OAI Identifier:

oai:repositorio.unbosque.edu.co:20.500.12495/2601

Acceso en línea:

http://hdl.handle.net/20.500.12495/2601
https://jamanetwork.com/journals/jama/fullarticle/10.1001/jamaoncol.2020.0409?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamaoncol.2020.0409
https://repositorio.unbosque.edu.co

Palabra clave:

Neoplasias pulmonares
Inmunoterapia
Docetaxel
Targeted and immune cancer therapy
Lung cancer
Oncology

Rights

openAccess

License

Acceso cerrado